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This report evaluates the signiﬁcance of antibody/bovine serum albumin (BSA) interactions as a risk factor for the diagnosis of
acute hepatitis E. Serum samples from 40 patients with acute hepatitis E and from 40 age/sex matched healthy adult subjects were
tested for IgA, IgG, and IgM by ELISA and by turbidimetric assay. BSA was used as a target to characterize changes in levels of
interacting immunoglobulins. Initial results obtained before removal of antibodies that interacted with BSA suggested that HEV
patients had increased levels of IgM in their sera. It was found that normal individuals had mean IgA, IgG, and IgM levels of
2.55mg/mL, 9.80mg/mL, and 1.73mg/mL, respectively while HEV patients had mean levels of 2.66mg/mL, 10.04mg/mL, and
2.01mg/mL (P<. 26, P<. 32, and P<. 0004). However, the mean level of IgM in HEV-infected sera after puriﬁcation from
antibodies that interacted with BSA was determined to be 1.72mg/mL indicating that there was no signiﬁcant diﬀerence in IgM
level in HEV patients compared to normal individuals (P<. 6). The presence of antibodies that interact with BSA might serve as a
diagnostic tool for detection of high-risk patients.
INTRODUCTION
Hepatitis E is the ﬁrst or second most important cause
of acute clinical hepatitis in many developing countries
of Asia, the Middle East, and North Africa. Hepatitis E
can occur sporadically or in epidemics and the peak clin-
ical attack rate usually occurs in young adults [1, 2, 3, 4].
Hepatitis E is caused by the hepatitis E virus (HEV)
which is a single-stranded sense strand RNA virus similar
to Caliciviruses that is enterically transmitted. Although
sporadic HEV infections have occurred in industrialized
nations, there is an unexpectedly high prevalence of an-
tibodies to HEV (anti-HEV) (as high as 21.3%) among
blood donors in the United States,wherehepatitis E is not
endemic [5]. Enzyme immunoassays based on recombi-
nant proteins of HEV have been used for most seropreva-
lence studies. A wide range of sensitivity and speciﬁcity
has been reported for these assays [6, 7, 8, 9]. This in-
formation implies that these assays might be unreliable
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for the diagnosis of HEV infection in areas where hep-
atitis E is not endemic. However, diagnosis of acute hep-
atitis E by detection of hepatitis E virus (HEV)-speciﬁc
immunoglobulin M (IgM) is an established procedure
[10, 11, 12, 13]. The measurement of antibodies to hep-
atitis E virus has been essential for understanding the epi-
demiology of hepatitis E. In this study, we investigated
whether serum level quantiﬁcation of HEV-speciﬁc IgA,
IgG, and IgM together furnished novel insight into infec-
tion and immunity.
Antibodies, which bind other proteins, may add an-
other facet to the abnormal immune response of HEV.
Variations in immunoreactivities and a limited window
for the persistence of antibodies to various epitopes may
account for such diagnostic failures. Bovine serum albu-
min is one of the most widely studied proteins; its struc-
ture is well known and its antigenic characteristics have
been described in several papers [14, 15]. The present
study was therefore designed to delineate heterophile an-
tibodyinterferenceinourELISAdetectionandtopropose
strategies for resolving the problem. We attempted to de-
termine whether there are speciﬁc aspects of using BSA to
determine whether antibodies that interact with BSA pro-
videanydiagnosticvalueasariskfactorforacutehepatitis
EusingELISA.Inaddition,thesensitivitiesofimmunoas-
says for antibodies to HEV may be increased by including
antigens such as BSA. Despite this complexity, data in this
study demonstrates more reliable results for IgM quan-
tiﬁcation after they have been puriﬁed from antibodies
that interact with BSA than for IgM quantiﬁcation with-
out such puriﬁcation.2005:4 (2005) BSA as a Diagnostic Tool for Detection of High-Risk HEV Patients 317
SUBJECTS AND METHODS
Anti-human IgA (G, M) antiserum (raised in rabbit),
human IgA (G, M), rabbit anti-human IgA (G, M) conju-
gated to horseradish peroxidase (HRP), and tetramethyl-
benzidine were purchased from Sigma (Sigma-Aldrich
Company Ltd, UK) and all other chemicals were supplied
from BDH (VWR International Ltd, UK).
Subjects
Informed patient consent was obtained in every case
and the use of blood for scientiﬁc studies was approved
by the local Ethical Committee. Sera were collected from
40 patients with a clinical diagnosis of acute hepatitis.
Serological diagnosis was based on the detection of anti-
hepatitisAvirus(anti-HAV)IgM,hepatitisBvirus(HBV)
markers (anti-HBV core IgM, HBV surface antigen, HBV
antigen), anti-hepatitis C virus (anti-HCV) IgG, and
anti-HEV IgG. Anti-HEV IgG was detected by using an
assay from Genelabs Technologies, Inc (USA). Forty pa-
tients who were diagnosed with hepatitis E fulﬁlled these
conditions and were admitted to the study. Forty partici-
pants unaﬀected by HEV were selected as a control group.
Aﬀected and unaﬀe c t e dg r o u p sw e r em a t c h e df o ra g ea n d
sex(medianagewas31yearsrangingfrom21to42years).
Medical history, physical examination, and routine labo-
ratory investigations were completely normal in all unaf-
fected subjects. They did not use any medication prior to
this study. All sera were collected within four months and
stored in small aliquots at −80◦C until tested under code.
Electrophoresisofimmuno-precipitates
onpolyacrylamidegel
Human serum samples were immuno-precipitated
with anti-human IgM developed in rabbit in the presence
or absence of BSA. Serum samples (25µL) were diluted
with either 1x PBS (475µL) or BSA (56µL, at a concen-
tration of 50mg/mL solution in 1x PBS) diluted with 1x
PBS (419µL) in addition, 75µL of anti-IgM antiserum
with 1x PBS (425µL). After dilution, the antiserum and
serum were mixed to give a ﬁnal volume of 1mL and
incubated for 1h at room temperature. The precipitate
was removed by centrifugation at 13000 rpm for 5min
in micro centrifuge and then washed with 200µL1 x
PBS. The antigen-antibody precipitate was dissolved in
50µL of 2x Laemmli sample buﬀer (0.125M Tris-HCl
pH (6.8), 0.1% (w/v) SDS, 20% (w/v) glycerol, 0.005%
(w/v) bromophenol blue) and then incubated at 95◦C
for 3min [16] .Af r a c t i o no ft h i sm i x t u r e( 2 5 µL) was
electrophoresed overnight on a 10% polyacrylamide
gel at a constant voltage of 45V at room temperature.
Following electrophoresis, proteins were visualized by
staining with Coomassie blue staining [17].
HumanimmunoglobulinmeasurementbyELISA
Coating antibody (anti-human IgA (IgG, IgM)
antiserum) was diluted 1 in 1000 in 1x coating buﬀer
(0.02M Tris-HCl, 1.5M N aCl pH 9.0) and 100µLw a s
added to each of the wells of a microtiter plate [18, 19].
After overnight incubation at 4◦C the plate was washed
4 times with PBST20 (0.1% (w/v) [Tween 20 in 1x PBS
(phosphate-buﬀered saline; 0.25M NaCl, 0.0268M KCl,
0.081M Na2HPO4,a n d0 .0146M KH2PO4)]).Sites unoc-
cupied by antibody were blocked by addition of 5% (w/v)
Marvel (dried skimmed milk) in PBS for 1h at room
temperature followed by washing 6 times with PBST20.
The human serum samples were initially diluted 1 in
2000 in 1x PBS, and 2 fold serial dilutions subsequently
performed on the plate. Diluted samples were allowed to
bind to the ﬁrst antibody and the plate was then washed
6 times in PBST20.
Rabbit anti-human IgA (IgG, IgM) conjugated to
HRP (second antibody) was diluted 1 in 1000 in 1x PBS,
100µL was added to each well of the microtiter plate,
incubated at room temperature for 1h and then washed 6
times in PBST20. The amount of bound second antibody
wasdeterminedbyadding200µLofthesubstratesolution
(tetramethylbenzidine 6mg/mL in 0.1M sodium acetate
buﬀer pH 6.0) to each well. After incubation in the dark
at room temperature for 20 min, the reaction was stopped
by adding 50µL of 10% (w/v) H2SO4 to each well. The
optical density of each sample was read with an ELISA
plate reader with a 450nm ﬁlter. A standard curve was
constructed by plotting absorbance against concentration
for the standard solutions and the concentration of im-
munoglobulin (mg/mL) in the samples was determined.
HumanimmunoglobulinMmeasurement
byturbidimetricassay
Human serum samples were titrated previously
against antisera to obtain the optimum optical densities
(optimal precipitation) [20]. Brieﬂy, 8µLo fh u m a n
serum samples was diluted with 492µL of 1x PBS and,
in addition, 25µL of anti-IgM antiserum (dev eloped
in rabbit) with 475µL of 1x PBS. After dilution, the
antiserum and serum were mixed and incubated for 1h at
room temperature.At the same time, the standard human
IgM was titrated by adding equal volumes of antiserum,
mixed well and incubated for 1h at room temperature.
The degree of precipitation was quantiﬁed by measuring
the optical density at 600nm. The concentration of IgM
(mg/mL)wascalculatedfromthestandarddilutionseries.
PuriﬁcationofHEV-infectedserafromtheeffect
ofantibodiesthatinteractwithBSA
Bovine serum albumin, 56µL, at a concentration of
50mg/mL solution in 1x PBS, pH 7.2, was mixed with
200µL of human serum samples (diluted 1 in 10) to
minimize further cross-reactivity to BSA. The absorption
was carried out for 1h at 37◦C, followed overnight at
4◦C. The human sera were clariﬁed by centrifugation at
10000 xg for 20min at 4◦C before testing [21, 22]. The
absorption of human sera with BSA completely removed
the positive reaction of BSA antibodies, and then the con-
centration of immunoglobulin present in each of these
samples was determined by ELISA as described above.318 Medhat Haroun 2005:4 (2005)
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Figure 1. Immuno-precipitation and polyacrylamide gel elec-
trophoresis of human serum samples with anti-human IgM.
Three HEV-infected serum samples were immuno-precipitated
with anti-IgM antiserum developed in rabbit in the absence
(lanes A, B, and C resp) or presence of BSA (lanes F, E, and D
resp). Lane H contained one normal serum sample in the ab-
senceofBSAandLaneGcontainedthesamenormalserumsam-
ple in the presence of BSA. Lane I represents standard human
IgM. H indicates positions of immunoglobulin heavy chains.
The precipitates were washed, dissolved in Laemmli sample
buﬀer, and analyzed by polyacrylamide gel electrophoresis.
Statisticalanalysis
Aftertabulatingthedata,thearithmeticmeanforeach
group was calculated using SPSS for Windows. The varia-
tion in each group was represented by the standard devia-
tion (SD). The means of the groups were compared to see
if the diﬀerences were signiﬁcant. Student t test was used
toassessthesigniﬁcanceofthediﬀerencebetweengroups.
RESULTS
The possibility that immunoglobulins from HEV-
infected sera bind and coprecipitate with BSA more than
do immunoglobulins from unaﬀected individuals was
investigated using polyacrylamide gel electrophoresis.
Three sera from HEV-infected patients and one serum
sample from an unaﬀected participant were immuo-
precipitated in the presence or absence of BSA and the
immunoprecipitates were electrophoresed on a polyacry-
lamide gel (Figure 1). Visual examination of Figure 1
shows that the pretreatment of HEV-infected sera with
BSA reduces the intensity of a band that coprecipitates
with the antigen-antibody complex and comigrates with
the IgM heavy chain.
It is not possible to diﬀerentiate between IgM and
other immunoglobulin heavy chains using polyacry-
lamide gel electrophoresis therefore ELISA measurements
were carried out with or without pretreatment with BSA
to determine if this increased interaction included IgM.
Sera from individuals unaﬀected or aﬀected with HEV
where allocated to two groups (A and B). Each serum
sample in group A (from unaﬀected individuals) was
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Figure 2. Serum IgM levels in groups of HEV-infected sera and
unaﬀected control measured by ELISA. Comparison of average
serum IgM (mean ± SD).
Table 1. Statistical analysis of IgA and IgG measured by ELISA.
(Values are mean ± SD.)
Study
Case
Serum IgA level Serum IgG level
group (mg/mL) (mg/mL)
1( n =40) Normal 2.55 ±0.51 9.80 ±0.98
3( n =40) HEV patients 2.66 ±0.39# 10.04 ±1.09∗
#P<. 26; ∗P<. 32 compared with normal individuals.
divided into two and assigned to groups 1 and 2 and each
sample in group B (from HEV-aﬀected individuals) was
assignedtogroups3and4.Groups1and3wereuntreated
while groups 2 and 4 were treated as outlined in “subjects
and methods” (“puriﬁcation of HEV-infected sera from
the eﬀect of antibodies that interact with BSA”). Unaf-
fected and HEV-aﬀected sera were pretreated with BSA to
investigatewhetherthiswouldaﬀecttheIgMlevelasmea-
suredbyELISA.Results(Figure2)demonstratedthatpre-
treatment of sera with BSA prior to ELISA aﬀected IgM
levels but that this dramatically reduced the level of IgM
in the sera from HEV patients (group 4) while sera from
unaﬀected individuals (group 2) were barely aﬀected by
this treatment. The quantitative analysis of serum IgM
level (mean ± SD) found that group 1 had a mean level of
IgM of 1.73 ± 0.154mg/mL which was lower than group
3( 2 .01±0.178mg/mL). This represented a signiﬁcant in-
crease in IgM level in the sera of group 3 compared to
group 1 (P<. 0004). On the contrary, the mean level of
IgM in the sera of group 4 was (1.72 ± 0.185mg/mL) and
there was no signiﬁcant diﬀerence between group 4 and
group 1 (P<. 6). In addition, the eﬀect of BSA treat-
mentonIgMlevelsintheseraofthecontrolgroup(group
2) was previously investigated and it was concluded that
the IgM level was within the normal level after treatment
(1.71 ± 0.158mg/m; P<. 16). However, nonsigniﬁcant
diﬀerences were found (Table 1) in both IgA and IgG level2005:4 (2005) BSA as a Diagnostic Tool for Detection of High-Risk HEV Patients 319
Table 2. Eﬀect of anti-BSA IgM antibodies on turbidimetric assay.
Sample ID
Group 1 Group 2 Decrease in IgM Group 3 Group 4 Decrease in IgM
Serum IgM level Serum IgM level concentration (%) Serum IgM level Serum IgM level concentration (%)
(mg/mL) (mg/mL) (mg/mL) (mg/mL)
1 1.55 1.51 2.6 2.41 .90 20.8
2 1.62 1.6 1.2 2.31 .4 39.1
3 1.57 1.56 0.6 2.21 .8 18.2
4 1.89 1.88 0.5 2.23 1.5 32.7
5 1.52 1.5 1.3 2.11 .8 14.3
6 1.88 1.88 0.0 1.98 1.83 7.6
7 1.71 .7 0.0 2.00 1.70 15
8 1.81 .78 1.1 2.41 .51 37.1
9 1.87 1.86 0.5 1.91 .8 5.3
10 1.89 1.86 1.6 2.21 .93 12.3
Mean 1.73 1.71 — 2.17 1.72
SD 0.154 0.158 0.173 0.183
—
of group 3 compared to normal individuals of group 1
(P<. 26 and P<. 32).
Theseresultswerevalidatedbymeasuringtheconcen-
t r a t i o no fs e r u mI g Mi n1 0s e l e c t e dH E Vi n f e c t e ds e r au s -
ing a turbidimetric assay (Table 2). The results from the
turbidimetric assay demonstrated that the diﬀerences be-
tween normal and HEV-infected sera that were not pre-
treatedwithBSA(groups1and3)weresigniﬁcant(1.73±
0.154mg/mL, 2.17±0.173mg/mL; P<. 001). In addition,
the levels of IgM detected with and without BSA pretreat-
ment in unaﬀected groups (groups 1 and 2) were essen-
tially identical (1.73±0.154mg/mL, 1.71±0.158mg/mL;
P<. 88), while in the aﬀected groups (groups 3 and
4) they were signiﬁcantly diﬀerent (2.17 ± 0.173mg/mL,
1.72 ± 0.183mg/mL; P<. 001). However, after pretreat-
ment with BSA, the means of groups 2 and 4 were essen-
tially identical (1.71±0.158mg/mL, 1.72±0.183mg/mL;
P<. 96). Hence pretreatment of sera from normal or
HEV-infected individuals with BSA leads to removal of
thediﬀerencesinIgMdetectedbyELISA orbyturbidime-
try.
DISCUSSION
Wehadaccesstoserialserumspecimenscollectedover
4monthsfrom40hepatitisEpatients.Thedemonstration
of antibodies that interact with BSA in HEV-infected sera
initiated a controversial debate on the utility of BSA anti-
bodies as a disease marker and on the role of BSA in HEV.
Our data suggest a high frequency of BSA/antibody cross-
reaction among HEV patients.
Previous studies demonstrated that IgM antibody lev-
els were very high after illness onset, declined a little over
several weeks, and then declined rapidly to low levels over
the next 4 to 6 months. This is typical of IgM responses
to other acute, self-limited, systemic viral infections
[23, 24]. The weeks-long duration of markedly elevated
IgM levels after disease onset means that diagnosis using
even relatively insensitive IgM detection methods should
be successful, even if patients come to medical atten-
tion late. Moreover, the months-long duration of IgM re-
s p o n s e st oH E Vm a yb eo fb e n e ﬁ tt oh e p a t i t i sEo u t b r e a k
investigations, since these typically commence months af-
ter the index case occurs. A sensitive IgM test should be
able to identify most disease cases from late-convalescent
phase serum specimens. Additionally, since many HEV
infections are known to be subclinical [25], sensitive tests
for IgM may enable identiﬁcation of all infected persons
rather than those with disease only. This problem has di-
rectedourresearchtowardsotherpossibleimmunological
factors likely to be present in HEV patients, in the attempt
to elucidate further the complex immuno-pathogenetic
interactions of the disease: our ﬁnding of BSA-antibody
interaction in HEV sera, leading to inaccuracies in IgM
estimation by ELISA, represents a move in this direction.
In order to overcome this problem of antibody inter-
action with BSA, the sera were preincubated with BSA to
eliminate this interaction. Interestingly, after removal of
antibodies that interact with BSA, the IgM level appears
to be similar between the aﬀected and unaﬀected groups
(Figure 2, Table 2) hence, after pretreatment with BSA,
IgM levels alone do not appear to be a reliable measure of
HEV infection.
The presence of antibodies that interact with BSA
in HEV-infected patients may reﬂect the increased pro-
duction of autoantibodies, and then lead to humoral
immune abnormalities. This is best explained by sug-
gesting that there is an interaction producing spuri-
ous immuno-precipitation as well as a circulating im-
munoglobulin which is capable of binding other autol-
ogous immunoglobulins which may well interact with
other immune factors, thus participating in vivo in the
compleximmunopathologicaleventswhichoccurinHEV
infected sera.320 Medhat Haroun 2005:4 (2005)
In conclusion, this study indicates that the presence of
antibodies reacting with BSA in sera from HEV-infected
patients may play a major pathogenetic role by the gener-
ation of autoantibodies. However, the time course for the
development of antibodies before onset of clinical HEV is
unknown, which might be most sensitive or speciﬁc for
predicting future development of the disease activity. The
high prevalence of elevated BSA/antibody interactions in
HEV patients enhances the clinical utility of this immune
marker due to polyclonal B cell activation or autoanti-
bodies generation. Finally, the presence of HEV antibod-
ies may help to explain the immunological abnormalities
and extra-hepatic disorders, thereby providing an oppor-
tunity for early intervention that may be used for pre-
dicting disease in at-risk populations. The ﬁndings in this
study can demonstrate the power of using BSA test to-
wards the prediction and diagnosis of complex diseases
such as HEV and may provide some new insights into an-
tibody response to HEV.
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